Title |
Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options
|
---|---|
Published in |
BMC Cancer, May 2015
|
DOI | 10.1186/s12885-015-1395-6 |
Pubmed ID | |
Authors |
Valeriya Semenisty, Inna Naroditsky, Zohar Keidar, Gil Bar-Sela |
Abstract |
Epithelioid hemangioendothelioma is a rare vascular tumor of borderline or low-grade malignancy. The lungs and liver are the two common primary organs affected. Metastatic disease was reported in more than 100 cases in the literature. However, no firm conclusions can be determined for recommended treatment options. The current case presents a patient with metastatic pulmonary epithelioid hemangioendothelioma to the cervical and mediastinal lymph nodes, lungs and liver that has been treated with pazopanib for more than two years with PET avid complete metabolic response in the mediastinum and lungs, and long-lasting stable disease. Target therapies that block VEGFR have a logical base in this rare malignancy. The current case is the first to report objective, long-lasting response to pazopanib. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 35 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 23% |
Researcher | 5 | 14% |
Other | 4 | 11% |
Student > Bachelor | 3 | 9% |
Student > Doctoral Student | 3 | 9% |
Other | 7 | 20% |
Unknown | 5 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 24 | 69% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Agricultural and Biological Sciences | 1 | 3% |
Unspecified | 1 | 3% |
Unknown | 7 | 20% |